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Introduction {#jdv15354-sec-0006}
============

Hidradenitis suppurativa (HS) is a chronic, recurrent, auto‐inflammatory skin disorder with limited effective treatment options.[1](#jdv15354-bib-0001){ref-type="ref"} Recently, treatment with apremilast for 16 weeks has demonstrated clinically meaningful improvement in moderate HS.[2](#jdv15354-bib-0002){ref-type="ref"} In this study (NCT03238469; EudraCT 2016‐000859‐27), twenty patients with moderate HS (HS‐PGA score of 3) were randomized in a 3 : 1 ratio to receive blinded treatment of apremilast 30 mg twice daily or placebo, respectively. Demographic and disease characteristics were similar between treatment arms. The mean age of the study population was 35 years (range: 21--64), most patients were female (17/20) and current smoker (16/20), the mean BMI was 32.7 ± standard deviation (SD) 6.2, and the mean abscess and inflammatory nodule (AN) count was 6.0 ± 1.8. The objective of this translational study was to evaluate the change in expression of inflammatory markers in lesional skin of HS patients receiving apremilast 30 mg twice daily for 16 weeks compared with placebo.

Material and Methods {#jdv15354-sec-0007}
====================

Ethical statement {#jdv15354-sec-0008}
-----------------

This investigator‐initiated trial was approved by the medical ethics committee of the Erasmus University Medical Center Rotterdam, The Netherlands (NL.57003.078.16), and conducted according to the Declaration of Helsinki principles. All patients provided written informed consent for study participation and use of their skin biopsies.

Biopsy procedures and sample processing {#jdv15354-sec-0009}
---------------------------------------

At baseline, two 5‐mm punch biopsies were taken: one was obtained from an erythematous, indurated, inflamed lesion, i.e. the index lesion (HSL), and one from the normal‐appearing unaffected non‐lesional (HSN) skin in the same anatomical area (Fig. [1](#jdv15354-fig-0001){ref-type="fig"}). Subsequent HSL skin samples were taken as close as possible to the previously biopsied index site at week 4 (early response) and week 16 (end of study). After sampling, biopsies were split whereby one half was processed for mRNA analysis of the biopsy, representing the *in vivo* gene expression, and the other half was cultured for *ex vivo* protein analysis. The supernatants and the biopsies in 250 μL lysis buffer containing 1% ß‐mercaptoethanol were transferred to a polypropylene tube and stored at −20°C until further analysis.

![Biopsy procedure in a patient with a good clinical response to apremilast. Note that all deep‐seated lesions have resolved. Erythematous lesions seen at week 16 are scars and superficial folliculitis. Panel (a; left) Baseline. A 5‐mm punch biopsy was obtained from an erythematous, indurated, inflamed lesion (arrow pointing to index lesion). An additional 5‐mm punch biopsy of the non‐lesional skin was taken from the same anatomical area to serve as control (circle within the square). Panel (b; middle) Week 4 and Panel (c; right) Week 16. Subsequent skin samples were taken as close as possible to the previously biopsied index site (small circles within dashed line).](JDV-33-761-g001){#jdv15354-fig-0001}

Ex vivo skin culture and protein quantification {#jdv15354-sec-0010}
-----------------------------------------------

After sampling, half of the 5‐mm biopsy was cultured for 24 h at 37°C in an atmosphere of 5% CO~2~ and 98% humidity in a transwell system (Netwell; Costar, Cambridge, MA, USA) as previously described.[3](#jdv15354-bib-0003){ref-type="ref"}, [4](#jdv15354-bib-0004){ref-type="ref"} In short, samples were placed in a 12‐well plate with the epidermis exposed to the air and the dermis immersed in 1 mL Iscove\'s modified Dulbecco\'s medium (Gibco, Paisley, UK) containing 0.5% human AB serum, penicillin (100 U/mL) and streptomycin (100 U/mL). A broad spectrum of 92 inflammatory markers was measured in the supernatant using the Olink Proseek Multiplex Inflammation panel (Olink Proteomics, Uppsala, Sweden).

In vivo gene expression {#jdv15354-sec-0011}
-----------------------

Total RNA was isolated using the GenElute Mammalian Total RNA Miniprep Kit (Sigma‐Aldrich, St. Louis, MA, USA), treated with 0.1 U/μL DNAse (Invitrogen, Carlsbad, CA, USA) and cDNA was synthesized with SuperScript II reverse transcriptase, random hexamer primers (Invitrogen) and oligo(dT)15 (Promega, Madison, WI, USA). Primers and probes were designed and chosen using ProbeFinder Software and the Universal Probe Library (Roche Applied Science, Indianapolis, IN, USA). *ABL1* was used as housekeeping gene. Real‐time quantitative PCR for 14 genes (*IFN‐ɣ, TNF‐α, IL‐1ß, IL‐6, IL‐8, IL‐10, IL‐23p19, IL‐12/23p40, IL‐17A, IL‐17F, IL‐31, CXCL‐10, CCL‐5* and *MPO*) was performed with the ViiA7 System and using the QuantStudio Real‐Time PCR Software version 1.3 (Applied Biosystems, Waltham, MA, USA).

Statistical analysis {#jdv15354-sec-0012}
--------------------

Protein data are presented as normalized protein expression (NPX), which are log2‐transformed arbitrary units. Relative mRNA expression levels for week 4 and week 16 were calculated using the 2^−ΔΔCT^ method using a baseline value of 1 for each individual sample.[5](#jdv15354-bib-0005){ref-type="ref"}

First, differentially expressed proteins at baseline were explored by calculating a fold change with the median NPX of HSL skin divided by the median NPX of HSN skin. If the fold change was more than 2, a Wilcoxon signed rank test was subsequently used to pairwise compare protein levels between HSL and HSN skin. Second, linear mixed effects models and associated ANOVA for repeated measures were calculated to compare inflammatory protein and mRNA expression levels between apremilast and placebo over time. Fixed effects were treatment, time and treatment × time. Third, the Spearman\'s rho was used to assess translational linkage, i.e. correlation between the levels of inflammation and the AN count.

A two‐sided *P*‐value below 0.05 was considered significant. *P*‐values were adjusted for multiple testing within each test using the Benjamini‐Hochberg approach. Statistical analyses were conducted in R Statistical Software version 3.5 (R Foundation for Statistical Computing, Vienna, Austria) using the lmerTest package.

Results {#jdv15354-sec-0013}
=======

At baseline, 17 proteins with a fold change \>2 were identified (Table [1](#jdv15354-tbl-0001){ref-type="table"}). The top‐five were IL‐17A (5), S100A12, CST5, IL‐12p40, CD6 (1) with fold changes ranging from 6.6 to 1638, respectively (FDR ≤0.044). Out of 92 Olink assays, 75 were included in the linear mixed effects models. The assays removed had less than 25% detectability including TNF‐α and IFN‐γ. Only the protein levels of S100A12 decreased over time in the apremilast vs. placebo group, statistically non‐significant after correction for multiple testing (*P* = 0.014, FDR = 0.186; Fig. [2](#jdv15354-fig-0002){ref-type="fig"}).

###### 

Proteins with a fold change \>2 in HSL vs. HSN skin at baseline

  \#   Protein    Fold change HSL/HSN   NPX HSL *n* = 20   NPX HSN *n* = 20   Unadj. *P*‐value   Adj. *P*‐value   Missing data           
  ---- ---------- --------------------- ------------------ ------------------ ------------------ ---------------- -------------- ------- ------
  1    CD6        1638                  3.5                2.0--4.1           0.002              0.0--0.2         3.4 e‐07       0.018   None
  2    IL‐12p40   38                    0.9                0.5--1.8           0.024              0.0--0.1         7.2 e‐06       0.038   7.5
  3    CST5       23                    0.9                0.6--1.1           0.041              0.0--0.1         6.1 e‐07       0.024   1.1
  4    S100A12    11                    4.5                3.1--6.3           0.4                0.4--0.8         2.7 e‐05       0.041   20.0
  5    IL‐17A     6.6                   3.1                1.8--3.8           0.5                0.5--0.6         2.9 e‐05       0.044   26.3
  6    TNFSF14    4.5                   3.4                2.5--4.1           0.8                0.4--1.0         1.0 e‐06       0.029   6.3
  7    AXIN1      4.4                   1.9                1.7--2.1           0.4                0.4--0.5         8.8 e‐07       0.026   8.8
  8    β‐NGF      3.2                   1.1                0.6--1.4           0.3                0.3--0.6         5.8 e‐04       0.047   15.0
  9    TNFSF11    3.1                   2.2                1.2--3.3           0.7                0.7--0.7         4.6 e‐07       0.021   28.8
  10   CD244      3.0                   2.7                2.3--3.1           0.9                0.9--0.9         1.1 e‐07       0.012   23.8
  11   CD5        3.0                   7.3                5.9--7.6           2.5                2.2--2.6         1.3 e‐08       0.003   None
  12   TNFRSF9    2.9                   6.4                5.2--7.6           2.2                1.8--2.7         1.3 e‐08       0.006   1.3
  13   OSM        2.9                   6.4                6.0--7.8           2.2                1.3--3.4         4.0 e‐06       0.035   3.8
  14   SIRT2      2.8                   5.0                4.5--5.4           1.8                1.5--1.9         1.9 e‐07       0.015   5.0
  15   GDNF       2.7                   2.9                2.0--3.8           1.1                0.8--1.2         1.6 e‐06       0.032   5.0
  16   IL‐18R1    2.3                   4.2                3.6--5.2           1.8                1.7--2.0         1.3 e‐08       0.009   None
  17   ST1A1      2.1                   1.5                0.8--1.8           0.7                0.5--1.2         1.3 e‐02       0.050   10.0

Missing data: samples with NPX‐values below background level throughout all samples, i.e. HSN and HSL baseline, HSL week 4 and HSL week 16. NPX: a high NPX value corresponds with a high protein concentration. Unadj. *P*‐value: unadjusted *P*‐value by Wilcoxon signed rank, NPX HSL vs. NPX HSN. Adj. *P*‐value (FDR): adjusted *P*‐value Benjamini Hochberg test, NPX HSL vs. NPX HSN.

FDR: false discovery rate; HS: hidradenitis suppurativa; HSL: HS lesional; HSN: HS non‐lesional; IQR: interquartile range; NPX: normalized protein expression.
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![Protein levels of S100A12 in patients receiving apremilast (*n* = 15) and placebo (*n* = 5), linear mixed effect model: *P* = 0.014, FDR = 0.186. *t*: week. Data at week 16 for two patients receiving apremilast are missing as these two patients discontinued after respectively week 4 and week 8.](JDV-33-761-g002){#jdv15354-fig-0002}

None of the 14 genes analysed by linear mixed effects models yielded significant differences. Only the relative mRNA expression of *IL‐17A* and *IL‐17F* demonstrated an evident but non‐significant downward trend in patients receiving apremilast vs. placebo (*P* \> 0.05; Fig. [3](#jdv15354-fig-0003){ref-type="fig"}). In addition, there was no correlation between S100A12 protein levels or *IL‐17A/F* mRNA expression and the favourable clinical response in the apremilast group as measured by the AN count (data not shown).

![Relative mRNA expression levels of *IL‐17A* and *IL‐17F* in patients receiving apremilast (*n* = 15) and placebo (*n* = 5). IL: interleukin; *t*: week. Panel (a; above) *IL‐17A*. At *t* = 16 in the apremilast group: one data point is out of the *y*‐axis range. Linear mixed effect model: *P* \> 0.05. Panel (b; below). *IL‐17F*. At both *t* = 4 and *t* = 16 in the apremilast group, one data point is out of the *y*‐axis range. Linear mixed effect model: *P* \> 0.05. Data at week 16 for two patients receiving apremilast are missing as these two patients discontinued after respectively week 4 and week 8.](JDV-33-761-g003){#jdv15354-fig-0003}

Discussion {#jdv15354-sec-0014}
==========

This translational study aimed to identify inflammatory skin markers in response to apremilast 30 mg twice daily for 16 weeks in patients with moderate HS, which showed positive clinical results and have been published previously.[2](#jdv15354-bib-0002){ref-type="ref"} However, S100A12 protein levels and *IL‐17A* and *IL‐17F* mRNA expression showed a clear but non‐significant decrease in patients receiving apremilast compared with placebo.

S100A12 (calgranulin C, EN‐RAGE) is a pro‐inflammatory, calcium‐binding antimicrobial protein that interacts with the receptor for advanced glycation end products (RAGE) and is overexpressed in various inflammatory skin diseases, e.g. psoriasis.[6](#jdv15354-bib-0006){ref-type="ref"}, [7](#jdv15354-bib-0007){ref-type="ref"} Previously, S100A8 and S100A9 (calprotectin or calgranulin A/B) have been demonstrated to be elevated in the serum and lesional skin of HS patients.[8](#jdv15354-bib-0008){ref-type="ref"}, [9](#jdv15354-bib-0009){ref-type="ref"} It is known that IL‐17 is a potent inducer of S100A8 and S100A9 in keratinocytes.[10](#jdv15354-bib-0010){ref-type="ref"}, [11](#jdv15354-bib-0011){ref-type="ref"} The other way around, S100A12 stimulates T cells to produce IL‐17A.[12](#jdv15354-bib-0012){ref-type="ref"} Thus, elevated levels of IL‐17A and S100A12 in HSL skin at baseline and the responsiveness of these inflammatory markers to apremilast treatment is not surprising. Moreover, apremilast\'s impact on the Th17 pathway was recently demonstrated by the significant reduction of IL‐17A and IL‐17F protein levels in the plasma of psoriasis patients.[13](#jdv15354-bib-0013){ref-type="ref"}

The non‐significant findings using a broad panel of inflammatory markers may be explained by the regression to the mean phenomenon, particularly at the individual level.[13](#jdv15354-bib-0013){ref-type="ref"} The highly inflammatory index lesions could have spontaneously improved over time in the context of the fluctuating nature of the disease, especially in the placebo group. The effect of regression to the mean increases with larger measurement variability.[14](#jdv15354-bib-0014){ref-type="ref"} Expanding the number of biopsies from index lesions, representing several degrees of inflammation, would theoretically be a solution. However, taking more biopsies would not be feasible for ethical reasons.

Another explanation for the decreased levels of inflammation over time in both groups could be that the inflammatory infiltrate of the index lesion was gradually reduced by successively taking biopsies from the same nodule. Moreover, the substrate for the foreign body inflammation such as hair fragments and keratin fibres, may have also been (partially) removed by the biopsy procedure.[15](#jdv15354-bib-0015){ref-type="ref"} In addition, this exploratory study might be underpowered which may also have resulted in non‐significant results.

Previously, two prospective uncontrolled studies investigating infliximab and ustekinumab in HS were also unable to link translational data to the clinical response.[16](#jdv15354-bib-0016){ref-type="ref"}, [17](#jdv15354-bib-0017){ref-type="ref"} However, in these studies, only inflammatory markers in serum were investigated. Strengths of our study include the placebo‐controlled trial design, the use of skin (target organ) instead of serum or plasma, and the standardized biopsy procedure of an index lesion. A limitation is the small study population.

In conclusion, this translational study investigating apremilast in moderate HS did not detect statistically significant changes in important inflammatory markers in lesional skin compared with placebo over 16 weeks of treatment, despite positive clinical findings. Nonetheless, related S100A12 and IL‐17A were significantly elevated in HSL skin and showed a decline only in the apremilast group. In addition, our findings highlight the challenge of assessing pharmacodynamics in the skin in a highly fluctuating inflammatory disease. A better translational model in clinical trials involving HS has yet to be developed.
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